TABLE 6.
Activity of methylenecyclopropane analogues against EBV VCA expression or DNA synthesis
| Drug | EC50 (μM) for EBV:
|
CC50 (μM) in Daudi cells | SIa | |
|---|---|---|---|---|
| VCA expression | DNA synthesis | |||
| ACV | 6.3 | 1.2 | >196 | >31.1 |
| QYL-284A | 3.2 | NTb | >230 | >71.9 |
| QYL-438 | 5.6 | 1.4 | >214 | >38.2 |
| QYL-468 | <0.4 | NT | >259 | >648 |
| QYL-546 | 6.9 | NT | >215 | >31.2 |
| QYL-678 | 0.05 | NT | >103 | >2,060 |
| QYL-685 | 3.8 | NT | 26.4 | 6.9 |
| QYL-769 | 11.8 | 1.7 | 27.9 | 2.4 |
| QYL-418 | 1.2 | NT | >191 | >159 |
| QYL-972 | >98 | NT | 3.7 | <0.04 |
| QYL-941 | 192 | NT | 162 | 0.84 |
| QYL-975 | >97 | NT | 97 | <1.0 |
a
SI, selectivity index (CC50/EC50) for EBV VCA results.
b
NT, not tested.